American Journal of Cardiology
Volume 106, Issue 6 , Pages 764-769, 15 September 2010

Relation of Elevated Plasma Renin Activity at Baseline to Cardiac Events in Patients With Angiographically Proven Coronary Artery Disease

  • Joseph B. Muhlestein, MD

      Affiliations

    • Intermountain Medical Center, Murray, Utah
    • University of Utah, Salt Lake City, Utah
    • Corresponding Author InformationCorresponding author: Tel: (801) 507-4701; fax: (801) 507-4789
    • ,
  • Heidi T. May, PhD

      Affiliations

    • Intermountain Medical Center, Murray, Utah
    • ,
  • Tami L. Bair, BS

      Affiliations

    • Intermountain Medical Center, Murray, Utah
    • ,
  • Margaret F. Prescott, PhD

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
    • ,
  • Benjamin D. Horne, PhD

      Affiliations

    • Intermountain Medical Center, Murray, Utah
    • University of Utah, Salt Lake City, Utah
    • ,
  • Richard White, PhD

      Affiliations

    • Research Evaluation Unit, Oxford PharmaGenesis Ltd., Oxford, United Kingdom
    • ,
  • Jeffrey L. Anderson, MD

      Affiliations

    • Intermountain Medical Center, Murray, Utah
    • University of Utah, Salt Lake City, Utah

Received 21 January 2010; received in revised form 23 April 2010 published online 02 August 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This study was supported by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

 Dr. Muhlestein has served on speakers' bureaux for Bristol-Myers Squibb, GSK, Merck, Novartis, and Sanofi-Aventis. Dr. Prescott is an employee of Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, and is thus eligible for Novartis stock and stock options. Dr. White is an employee of Oxford PharmaGenesis Ltd., which has received project funding from Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

PII: S0002-9149(10)01036-2

doi:10.1016/j.amjcard.2010.04.040

American Journal of Cardiology
Volume 106, Issue 6 , Pages 764-769, 15 September 2010

Article Tools

* Image Usage & Resolution